Fig. 4

FGFR-agonist programmed transcriptional profile of NPCs. (A) Comparative gene expression heatmaps in NPCs treated with FGFR-agonist and bFGF. The heatmaps display the transcriptional profiles of NPCs exposed to FGFR-agonist or bFGF for 10 days, relative to untreated NPCs (None). Both upregulated (red) and downregulated (green) gene profiles demonstrate a high degree of similarity between the two treatment conditions. (B) Functional enrichment analysis of upregulated DEGs in FGFR-agonist-treated NPCs versus untreated NPCs, utilizing gene ontology (GO) terms. It displays the top 10 significantly enriched GO terms, with the corresponding number of genes in parentheses. (C) A KEGG pathway enrichment analysis of the upregulated DEGs in FGFR-agonist-treated NPCs compared to untreated NPCs, indicating the top 20 significantly enriched pathways, denoted by the -log10 (adjusted p-value). (D) A similar KEGG pathway enrichment analysis for downregulated DEGs in FGFR-agonist-treated NPCs compared to untreated NPCs shows the top 20 significantly enriched pathways. (E) This panel presents a pathway enrichment analysis of differentially expressed transcripts in FGFR-agonist-treated NPCs versus untreated NPCs, based on KEGG pathway classification, highlighting the top 20 significantly enriched pathways. (F) A KEGG pathway enrichment cnet plot for upregulated DEGs in FGFR-agonist-treated NPCs compared to untreated NPCs. The nodes symbolize KEGG pathways, and the edges signify overlapping genes between pathways. Node size corresponds to the number of genes in the pathway, while node color represents the -log10 (adjusted p-value) of enrichment